You Position: Home > Paper

C-MET in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors

( views:347, downloads:97 )
Author:
No author available
Journal Title:
International Journal of Respiration
Issue:
19
DOI:
10.3760/cma.j.issn.1673-436X.2012.019.017
Key Word:
C-MET;酪氨酸激酶抑制剂;非小细胞肺癌;表皮生长因子受体;耐药,肝细胞生长因子;C-MET;Tyrosine Kinase Inhibitors;Non-small cell lung cancer;Epidermal growth factor receptor;Resistance;Hepatocyte growth factor

Abstract: In recent years epidermal growth factor receptor (EGFR) inhibitor is atreatment a major treatment of non-small cell lung cancer (NSCLC).But with the widespread clinical application of resistance as a new difficulty.Now researchers have discovered the main resistance mechanisms is C-MET oncogene amplification.C-MET is a proto oncogene,a protein product of hepatocyte growth factor/scatter factor (HGF/SF) receptor with tyrosine activity.The amplification of C-MET can activated Erb3-PI3K signaling pathway which result in NSCLC resistant to the EGFR-TKI.The patients who resist to EGFR-TKI for about 20% were due to the amplification of C MET gene.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn